These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3278241)

  • 1. The management of clinically localized prostate cancer. A summary of the Consensus Statement of the National Institutes of Health.
    Halperin EC; Fraser RW; Hughes J
    N C Med J; 1988 Feb; 49(2):75-9. PubMed ID: 3278241
    [No Abstract]   [Full Text] [Related]  

  • 2. Consensus statement: the Management of Clinically Localized Prostate Cancer. National Institutes of Health Consensus Development Panel.
    NCI Monogr; 1988; (7):3-6. PubMed ID: 3050539
    [No Abstract]   [Full Text] [Related]  

  • 3. Consensus development summaries. The management of clinically localized prostate cancer. National Institutes of Health.
    Conn Med; 1987 Sep; 51(9):607-10. PubMed ID: 3311616
    [No Abstract]   [Full Text] [Related]  

  • 4. National Institutes of Health Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Bethesda, Maryland, June 15-17, 1987.
    NCI Monogr; 1988; (7):1-174. PubMed ID: 3050532
    [No Abstract]   [Full Text] [Related]  

  • 5. The management of clinically localized prostate cancer.
    Natl Inst Health Consens Dev Conf Consens Statement; 1987 Jun 15-17; 6(10):1-6. PubMed ID: 3317009
    [No Abstract]   [Full Text] [Related]  

  • 6. NIH Consensus Development Conference. Management of clinically localized prostate cancer.
    Oncology (Williston Park); 1987 Nov; 1(9):46-9, 54. PubMed ID: 3079494
    [No Abstract]   [Full Text] [Related]  

  • 7. The management of clinically localized prostate cancer. National Institutes of Health Consensus Development Conference, June 15-17, 1987.
    J Urol; 1987 Dec; 138(6):1369-75. PubMed ID: 3316713
    [No Abstract]   [Full Text] [Related]  

  • 8. Consensus conference. The management of clinically localized prostate cancer.
    JAMA; 1987 Nov; 258(19):2727-30. PubMed ID: 3312666
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant chemotherapy for breast cancer. National Institutes of Health Consensus Development Conference Statement.
    Natl Inst Health Consens Dev Conf Consens Statement; 1985; 5(12):5 p.. PubMed ID: 3908920
    [No Abstract]   [Full Text] [Related]  

  • 10. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urologic cancer research at the National Cancer Institute.
    Chiarodo A
    Semin Urol; 1993 Feb; 11(1):2-6. PubMed ID: 8465123
    [No Abstract]   [Full Text] [Related]  

  • 12. National Institutes of Health consensus development conference statement CEA (carcinoembryonic antigen): its role as a marker in the management of cancer.
    J Ark Med Soc; 1981 Jun; 78(1):65-8. PubMed ID: 6454681
    [No Abstract]   [Full Text] [Related]  

  • 13. National Institutes of Health Consensus Development Conference Statement. CEA (carcinoembryonic antigen): its role as a marker in the management of cancer.
    J Okla State Med Assoc; 1981 Oct; 74(10):338-40. PubMed ID: 7338736
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer update: 2005.
    Ryan CJ; Small EJ
    Curr Opin Oncol; 2006 May; 18(3):284-8. PubMed ID: 16552242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.
    Levinson A; Nagler EA; Lowe FC
    Urology; 2005 Jan; 65(1):91-4. PubMed ID: 15667871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future directions in prostate cancer treatment: an oncologist's perspective.
    Hussain M
    Prostate Suppl; 1996; 6():26-30. PubMed ID: 8630225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Institutes of Health Consensus Development Conference Statement-CEA (carcinoembryonic antigen): its role as a marker in the management of cancer.
    Md State Med J; 1981 Jul; 30(7):48-50. PubMed ID: 7278383
    [No Abstract]   [Full Text] [Related]  

  • 19. [Histopathologic changes due to combination of androgen deprivation and transurethral microwave thermotherapy in patients with localized prostate cancer].
    Suzuki R; Jujo Y; Koshiba K; Hoshiai O; Endo T; Aihara M; Nakajo H; Ohori M
    Hinyokika Kiyo; 2009 Feb; 55(2):79-85. PubMed ID: 19301612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.